tirzepatide surmount 4 for the treatment of obesity: Rationale and design of the clinical development program - Roux - 2023 - Obesity Tirzepatide Demonstrates Sustained Weight Loss

Colonizing with the selected bacteria or administering microbial metabolites, such as short-chain fatty acids (SCFAs), could promote or mitigate disease progression 92,95,96 and motor behavior 92,95,97,98,99

What is the immunogenicity concern

Common additions include: Benzyl alcohol as a preservative in multi-dose vials Buffer solutions to maintain optimal pH (typically around 4.5 to 5.0 for tirzepatide) Mannitol or trehalose as stabilizers in lyophilized formulations These additives affect stability profiles

Procedure Because every weight loss treatment plan is custom-tailored to each individual, procedures may vary